Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors

被引:640
作者
Issaeva, N
Bozko, P
Enge, M
Protopopova, M
Verhoef, LGGC
Masucci, M
Pramanik, A
Selivanova, G [1 ]
机构
[1] Karolinska Inst, Ctr Microbiol & Tumor Biol, SE-17177 Stockholm, Sweden
[2] Karolinska Inst, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden
关键词
D O I
10.1038/nm1146
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In tumors that retain wild-type p53, its tumor-suppressor function is often impaired as a result of the deregulation of HDM-2, which binds to p53 and targets it for proteasomal degradation. We have screened a chemical library and identified a small molecule named RITA ( reactivation of p53 and induction of tumor cell apoptosis), which bound to p53 and induced its accumulation in tumor cells. RITA prevented p53 - HDM-2 interaction in vitro and in vivo and affected p53 interaction with several negative regulators. RITA induced expression of p53 target genes and massive apoptosis in various tumor cells lines expressing wild-type p53. RITA suppressed the growth of human fibroblasts and lymphoblasts only upon oncogene expression and showed substantial p53-dependent antitumor effect in vivo. RITA may serve as a lead compound for the development of an anticancer drug that targets tumors with wild-type p53.
引用
收藏
页码:1321 / 1328
页数:8
相关论文
共 46 条
  • [1] SUPPRESSION OF HUMAN COLORECTAL-CARCINOMA CELL-GROWTH BY WILD-TYPE-P53
    BAKER, SJ
    MARKOWITZ, S
    FEARON, ER
    WILLSON, JKV
    VOGELSTEIN, B
    [J]. SCIENCE, 1990, 249 (4971) : 912 - 915
  • [2] iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human
    Bergamaschi, D
    Samuels, Y
    O'Neil, NJ
    Trigiante, G
    Crook, T
    Hsieh, JK
    O'Connor, DJ
    Zhong, S
    Campargue, I
    Tomlinson, ML
    Kuwabara, PE
    Lu, X
    [J]. NATURE GENETICS, 2003, 33 (02) : 162 - 167
  • [3] Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo
    Bottger, A
    Bottger, V
    Sparks, A
    Liu, WL
    Howard, SF
    Lane, DP
    [J]. CURRENT BIOLOGY, 1997, 7 (11) : 860 - 869
  • [4] Disruption of p53 in human cancer cells alters the responses to therapeutic agents
    Bunz, F
    Hwang, PM
    Torrance, C
    Waldman, T
    Zhang, YG
    Dillehay, L
    Williams, J
    Lengauer, C
    Kinzler, KW
    Vogelstein, B
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (03) : 263 - 269
  • [5] Requirement for p53 and p21 to sustain G2 arrest after DNA damage
    Bunz, F
    Dutriaux, A
    Lengauer, C
    Waldman, T
    Zhou, S
    Brown, JP
    Sedivy, JM
    Kinzler, KW
    Vogelstein, B
    [J]. SCIENCE, 1998, 282 (5393) : 1497 - 1501
  • [6] Mdm2 binding to a conformationally sensitive domain on p53 can be modulated by RNA
    Burch, LR
    Midgley, CA
    Currie, RA
    Lane, DP
    Hupp, TR
    [J]. FEBS LETTERS, 2000, 472 (01) : 93 - 98
  • [7] A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines
    Chène, P
    Fuchs, J
    Bohn, J
    García-Echeverría, C
    Furet, P
    Fabbro, D
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 2000, 299 (01) : 245 - 253
  • [8] Inhibiting the p53-MDM2 interaction:: An important target for cancer therapy
    Chène, P
    [J]. NATURE REVIEWS CANCER, 2003, 3 (02) : 102 - 109
  • [9] CRYSTAL-STRUCTURE OF A P53 TUMOR-SUPPRESSOR DNA COMPLEX - UNDERSTANDING TUMORIGENIC MUTATIONS
    CHO, YJ
    GORINA, S
    JEFFREY, PD
    PAVLETICH, NP
    [J]. SCIENCE, 1994, 265 (5170) : 346 - 355
  • [10] D'Orazi G, 2000, J GENE MED, V2, P11